RNA-binding protein FUS, Novus Biologicals, NBP2-52874

Our team has carried out an in-depth review of the published scientific literature to identify papers and reports using antibodies directed against the human RNA-binding protein Fused-in-Sarcoma, followed by extraction and evaluation of the available data to assess performance according to the pAbmAbs rating criteria.

YCharOS is conducting a large head-to-head study comparing 18 commercially available research antibodies against the human RNA-binding protein Fused-in-Sarcoma encoded by FUS.

The collection of antibodies was tested using HeLa WT and FUS KO cells in the applications WB (WT and KO cell lysates, 30 µg protein), IP (WT cell lysate), IF (WT and KO cells), and flow cytometry (WT and KO cells). Some antibodies were evaluated across multiple applications, whereas others were tested exclusively by flow cytometry, all according to YCharOS standard protocols (see reference).

In WB (1:1000 Ab dilution) NBP2-52874 detected an intense band of appr. 70 kDa in WT cell lysate with no corresponding band observed in KO cell lysate. No band was observed following IP (1 µg Ab used). In IF (1:1000 Ab dilution), a clear intense staining was observed in WT cells with no background staining in KO cells. Flow cytometry (0.2 μg/mL antibody) showed overlapping fluorescence intensity distributions for WT and KO cells, with only a small shift between the two populations. The WT signal was comparable to the KO and background levels, indicating an absence of specific antibody binding, suggesting that this antibody does not specifically detect the target by flow cytometry.

We highly encourage other scientists to share their observations.